BSE filing, BSE: 542678. Summary written from the filing by ALFA Finder's alert engine.
Cian Healthcare Ltd: key numbers
- Share price
- ₹32.20
- Market cap
- ₹80.50 Cr
- Revenue (annual)
- ₹28.30 Cr
- Net profit (annual)
- ₹-23.29 Cr
- Promoter holding
- 95.00%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cian Healthcare Ltd
All →Cian Healthcare Merger & Restructuring
Cian Healthcare disposed of its Dr. Smiths Biotech subsidiary under an NCLT-approved resolution plan. Its equity was cancelled with nil consideration receivable.
Cian Healthcare Insolvency Petition
Cian Healthcare's subsidiary Dr. Smiths Biotech ceased to be a subsidiary after NCLT approved Ananta Medicare's resolution plan. Equity was extinguished with no consideration received.
Cian Healthcare Other Announcement
Cian Healthcare filed its quarterly shareholding pattern. The company disclosed it is working to restore public shareholding levels following an NCLT-approved resolution plan.
Cian Healthcare Annual General Meeting
Cian Healthcare Ltd held its 23rd AGM on September 29, 2026, approving financial statements, director re-appointment, auditor appointment, and the 2026 Employee Stock Option Scheme.
Cian Healthcare Annual Report
Cian Healthcare Limited has filed its Annual Report for the financial year ended March 31, 2026, and the Notice of its 23rd Annual General Meeting.
Cian Healthcare Employee Stock Options
Cian Healthcare has instituted an Employee Stock Option Scheme (ESOS 2026), covering up to 10 million shares. No grants have been issued yet under this plan.
Other management change announcements
All →Vertex Securities Management Change
Vertex Securities appointed Ms. Unni as Independent Director and Mr. Iyer as CFO, effective October 2026. Both roles were approved at the 28 October board meeting.
Kirloskar Brothers Management Change
Kirloskar Brothers' Independent Directors Vivek Pendharkar and Rekha Sethi completed their 5-year terms on 28 Oct 2026. They ceased from the Board and all committees.
iStreet Network Management Change
iStreet Network Ltd announced the resignation of Non-Executive Non-Independent Director Mr. Yash Maheshwari effective 13 October 2026. No financial impact is indicated.
Transgene Biotek Management Change
Transgene Biotek's statutory auditors Eswara Rao & Co. resigned effective 28 October 2026 citing pre-occupation. The company will appoint new auditors per applicable regulations.
Mobavenue AI Tech Management Change
Mobavenue AI Tech appointed Vikram Sheth as Chief of Corporate Development and Investor Relations. He will lead fundraising, acquisitions and investor relations.
Hexaware Technologies Management Change
Hexaware appointed Arjun Shah and Gregory Zeluck as Non-Executive Directors from 28 October 2026. Directors Neeraj Bharadwaj and Julius Genachowski resigned, and Girish Pai's resignation is effective 13 November 2026.